Johnson & Johnson was among the investors in a $54.5m series A round for CuraSen Therapeutics, which is commercialising research from Stanford University.
CuraSen Therapeutics, a US-based neurodegenerative disease treatment developer based on research at Stanford University, has completed a $54.5m series A round led by venture capital firm New Leaf Venture Partners.
Johnson & Johnson Innovation – JJDC, the strategic investment vehicle for medical product group Johnson & Johnson, contributed to the round, which also included VC firms Longitude Capital, Alta Partners and Pappas Capital as well as funds managed by investment adviser Tekla Capital Management.
CuraSen is working on…
